Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN4 | P29074 | 1/20 | 0.35 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114147 | 0.90 | CHEK1 (0.53) | CHEK1GPR3TP53LMNARXFP1 | |
| SCHEMBL11104184 | 0.83 | CHEK1 (0.42) | CHEK1PTPN2PTPN1PTPN4PTPN9 | |
| SCHEMBL11402053 | 0.81 | CHEK1 (0.41) | CHEK1 | |
| SCHEMBL9680854 | 0.81 | CHEK1 (0.41) | CHEK1 | |
| SCHEMBL11098855 | 0.81 | CHEK1 (0.41) | CHEK1TP53LMNATTR | |
| SCHEMBL11102892 | 0.79 | CHEK1 (0.43) | CHEK1GPR3PTPN2PTPN1PTPN4 | |
| SCHEMBL11096171 | 0.79 | CHEK1 (0.40) | CHEK1 | |
| SCHEMBL11104253 | 0.78 | CHEK1 (0.39) | CHEK1TP53LMNAKMT2A | |
| SCHEMBL11036902 | 0.78 | GPR3 (0.55) | GPR3TP53LMNAPTPN1RXFP1 | |
| SCHEMBL11099356 | 0.77 | MEN1 (0.47) | CHEK1TSHRMEN1KMT2ATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231656-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | claimed |
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | claimed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | claimed |
| EP-0463636-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1992-01-02 | — | — | EP | claimed |
| US-4876246-A | Benzo[a]phenothiazines and hydro-derivatives for inhibiting leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1989-10-24 | — | — | US | claimed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| US-4558037-A | A DIBENZOTHIEPIN COMPOUND AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | MERCK & CO., INC. (US) | 1985-12-10 | — | — | US | claimed |
| EP-0029587-A1 | 3-Hydroxymethyldibenzo(b,f)thiepins and dibenzo(b,f)thiepin-3-carboxaldehydes as prostaglandin antagonists, process for their preparation and pharmaceutical compositions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1981-06-03 | — | — | EP | claimed |
| US-4237160-A | 3-Hydroxymethyldibenzo[b,f]thiepins as prostaglandin antagonists | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1980-12-02 | — | — | US | claimed |
| JP-1061425-A | — | — | None | — | — | JP | disclosed |
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| EP-0029587-A1 | 3-Hydroxymethyldibenzo(b,f)thiepins and dibenzo(b,f)thiepin-3-carboxaldehydes as prostaglandin antagonists, process for their preparation and pharmaceutical compositions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4237160-A | 3-Hydroxymethyldibenzo[b,f]thiepins as prostaglandin antagonists | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1980-12-02 | — | — | US | disclosed |
| JP-S06461425-A | — | — | 0001-01-01 | — | — | JP | disclosed |